Autoinflammatory & rare systemic diseases
Biologic–biologic and biologic–JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases
Authors' conclusion
ACT offers significant clinical benefits for patients with difficult-to-treat SAIDs, though challenges such as secondary loss of efficacy and infection risks remain.
Study context
- Population
- Patients with refractory systemic autoinflammatory diseases (SAIDs) treated with advanced combination therapy (median age 30 years [range 4–76])65 advanced combination therapy (ACT) regimens
- Participants
- 38 patients
- Outcome
- Treatment response: composite of corticosteroid dose, C-reactive protein (CRP) and clinical improvement, categorised as non-response, partial response or complete response
Methodological detailsobservational, longitudinal
- Observational
- Longitudinal
Main finding
As reported in the abstract
Treatment response after multiple ACT trials
Complete response
21 patients
55.3%
Partial response
12
31.6%
No response
5
13.1%
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Remaining on ACT at final follow-up | ACT 68% |
- Remaining on ACT at final follow-up — Median treatment duration (range)
- 60 months (range, 11-186)
ACT regimens discontinued (lack of efficacy, secondary loss of response, or AEs)
- Regimens discontinued, of 65
- 39
Original publication
Biologic–biologic and biologic–JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases. Semin Arthritis Rheum. Published 24 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →